Cefozopran

A fourth-generation cephalosporin antibacterial agent with a broad spectrum of activity against Gram-positive and Gram-negative bacteria. Cefozopran has a 1-methyltetrazolethiol (MTT) moiety at C-3 of its cephalosporin core.

Also Known As:

Networked: 46 relevant articles (4 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ikawa, Kazuro: 4 articles (04/2008 - 10/2007)
2.	Ikeda, Kayo: 4 articles (04/2008 - 10/2007)
3.	Morikawa, Norifumi: 4 articles (04/2008 - 10/2007)
4.	Kobayashi, Ryoji: 3 articles (11/2014 - 12/2008)
5.	Suzuki, Daisuke: 3 articles (11/2014 - 12/2011)
6.	Tanimoto, Mitsune: 2 articles (01/2015 - 01/2004)
7.	Sano, Hirozumi: 2 articles (11/2014 - 08/2014)
8.	Kobayashi, Kunihiko: 2 articles (08/2014 - 12/2008)
9.	Yasuda, Kazue: 2 articles (08/2014 - 12/2008)
10.	Iguchi, Akihiro: 2 articles (12/2011 - 12/2008)

Related Diseases

1.	Infections 01/01/1999 - "[Pharmacokinetic analysis of cefozopran in neonatal infections--population pharmacokinetics using nonmem]." 07/01/1998 - "When cefozopran was administered subcutaneously twice a day for 1-3 days starting 2 days after infection, dose- and duration-dependent effects were observed and all mice treated with 20 mg/kg of cefozopran for 3 days survived. " 11/01/1994 - "A new parenteral cephem, cefozopran (CZOP), was evaluated for its safety and efficacy in 21 children with acute infections. " 04/01/2008 - "The probability of attaining the pharmacodynamic exposure target (70% of the time above the MIC; i.e., probability of target attainment; PTA) was 94.9% and 100%, respectively, against Escherichia coli and Klebsiella species with 1 g every 12 h; however, 1 g every 8 h was required for a PTA value of 90% or more at an MIC of 8 microg/ml. We consider that these results will help clinicians to better understand the penetration into and exposure of cefozopran in the female genital cavity, while also helping to rationalize the dosage of this agent for gynecological-surgery infections." 08/01/1998 - "[Clinical evaluation of cefozopran for infections associated with hematological malignancies]."
2.	Pneumonia (Pneumonitis) 12/01/1997 - "The efficacy, safety and pharmacokinetics of cefozopran (CZOP) were evaluated in neonates and the following results were obtained: 1. Of the 12 patients treated with CZOP, judgment of clinical efficacy was evaluable in 10 patients (including 5 with pneumonia and 3 with urinary tract infections). " 05/01/1999 - "Drug sensitivity of clinically isolated bacteria to cefozopran (CZOP), which is a new cephem antibiotic, was investigated, and the usefulness of the drug was evaluated from the viewpoint of bacteriological and clinical (pneumonia) break points. " 11/01/1994 - "Cefozopran (CZOP, SCE-2787) was given intravenously to 12 children with acute bacterial infections including 9 with acute pneumonia, 1 each with acute pyothorax, impetigo and staphylococcal scalded skin syndrome. " 12/01/2001 - "We compared the bacteriological, pharmacological and histopathological effects of parenterally administered ciprofloxacin (CPFX) to those of imipenem/cilastatin (IMP/CS) and cefozopran (CZOP) in a murine model of mucoid Pseudomonas aeruginosa pneumonia mimicking ventilator-associated pneumonia. " 07/01/2001 - "Efficacy of panipenem/betamipron (PAPM/BP) against experimental pneumonia caused by penicillin-resistant Streptococcus pneumoniae (PRSP: MIC of benzylpenicillin, > or = 1.56 micrograms/ml) in mice was compared with those of imipenem/cilastatin (IPM/CS), meropenem (MEPM), cefozopran (CZOP), ceftriaxone (CTRX), ampicillin (ABPC), and vancomycin (VCM). "
3.	Pyometra 03/01/1998 - "We evaluated the efficacy of cefozopran (CZOP) using polymicrobial pyometra rats. " 03/01/1998 - "Therapeutic effects of cefozopran on polymicrobial infections associated with Enterococcus faecalis in a Rat pyometra model."
4.	Soft Tissue Infections 01/01/1993 - "The potent therapeutic effect of cefozopran in those experimental infections in mice suggests that it would be effective against respiratory tract, urinary tract, and soft tissue infections caused by a variety of gram-positive and gram-negative bacteria in humans."
5.	Pneumococcal Meningitis (Streptococcus pneumoniae Meningitis) 07/01/1998 - "Therapeutic efficacy of cefozopran in a murine model of haematogenous pneumococcal meningitis."

Related Drugs and Biologics

1.	Imipenem Drug Combination Cilastatin (Primaxin)
2.	Meropenem (Merrem)
3.	Therapeutic Uses
4.	Ceftriaxone (Ceftriaxon)
5.	Ampicillin (Omnipen)
6.	Vancomycin
7.	Penicillins (Penicillin)
8.	Penicillin G (Benzylpenicillin)
9.	panipenem-betamipron
10.	Tazobactam Drug Combination Piperacillin (Zosyn)

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Injections
3.	Cardiopulmonary Resuscitation (CPR)
4.	Gynecologic Surgical Procedures (Gynecologic Surgery)
5.	Injections